Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study by Morris, Van K, MD, Salem, Mohamed E, MD, Nimeiri, Halla, MD, Iqbal, Syma, MD, Singh, Preet, MD, Ciombor, Kristen, MD, Polite, Blase, MD, Deming, Dustin, MD, Chan, Emily, MD, Wade, James L, MD, Xiao, Lianchun, MS, Bekaii-Saab, Tanios, Prof, Vence, Luis, PhD, Blando, Jorge, DVM, Mahvash, Armeen, MD, Foo, Wai Chin, MD, Ohaji, Chimela, MD, Pasia, Manolo, BSN, Bland, Gail, BS, Ohinata, Aki, PAC, Rogers, Jane, PharmD, Mehdizadeh, Amir, MA, Banks, Kimberly, MS, Lanman, Richard, MD, Wolff, Robert A, Prof, Streicher, Howard, MD, Allison, James, Prof, Sharma, Padmanee, Prof, Eng, Cathy, Prof

Get full text

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma by Shroff, Rachna T, Yarchoan, Mark, O'Connor, Ashley, Gallagher, Denise, Zahurak, Marianna L, Rosner, Gary, Ohaji, Chimela, Sartorius-Mergenthaler, Susan, Subbiah, Vivek, Zinner, Ralph, Azad, Nilofer S

Get full text

Erratum: The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma by Shroff, Rachna T, Yarchoan, Mark, O'Connor, Ashley, Gallagher, Denise, Zahurak, Marianna L, Rosner, Gary, Ohaji, Chimela, Sartorius-Mergenthaler, Susan, Parkinson, Rose, Subbiah, Vivek, Zinner, Ralph, Azad, Nilofer S

Get full text

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma by Shroff, Rachna T, Yarchoan, Mark, O'Connor, Ashley, Gallagher, Denise, Zahurak, Marianna L, Rosner, Gary, Ohaji, Chimela, Sartorius-Mergenthaler, Susan, Parkinson, Rose, Subbiah, Vivek, Zinner, Ralph, Azad, Nilofer S

Get full text

STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harbo... by Subbiah, Vivek, McMahon, Caitlin, Patel, Shreyaskumar, Zinner, Ralph, Silva, Elvio G, Elvin, Julia A, Subbiah, Ishwaria M, Ohaji, Chimela, Ganeshan, Dhakshina Moorthy, Anand, Deepa, Levenback, Charles F, Berry, Jenny, Brennan, Tim, Chmielecki, Juliann, Chalmers, Zachary R, Mayfield, John, Miller, Vincent A, Stephens, Philip J, Ross, Jeffrey S, Ali, Siraj M

Get full text

Abstract CT131: NCI9673 phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal: Immunologic correlates of response by Morris, Van, Mahvash, Armeen, Vence, Luis, Blando, Jorge, Wolff, Robert A, Ohinata, Aki, Ohaji, Chimela, Allison, James, Sharma, Padmanee, Eng, Cathy

Get full text

Abstract CT131: NCI#9673 phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal: Immunologic correlates of response by Morris, Van, Mahvash, Armeen, Vence, Luis, Blando, Jorge, Wolff, Robert A., Ohinata, Aki, Ohaji, Chimela, Allison, James, Sharma, Padmanee, Eng, Cathy

Get full text

A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma by Kaseb, Ahmed Omar, Kappadath, S Cheenu, Lee, Sunyoung S, Raghav, Kanwal Pratap, Mohamed, Yehia I, Xiao, Lianchun, Morris, Jeffrey S, Ohaji, Chimela, Avritscher, Rony, Odisio, Bruno C, Kuban, Joshua, Abdelsalam, Mohamed E, Chasen, Beth, Elsayes, Khaled M, Elbanan, Mohamed, Wolff, Robert A, Yao, James C, Mahvash, Armeen

Get full text

A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90 Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma by Kaseb, Ahmed Omar, Kappadath, S Cheenu, Lee, Sunyoung S, Raghav, Kanwal Pratap, Mohamed, Yehia I, Xiao, Lianchun, Morris, Jeffrey S, Ohaji, Chimela, Avritscher, Rony, Odisio, Bruno C, Kuban, Joshua, Abdelsalam, Mohamed E, Chasen, Beth, Elsayes, Khaled M, Elbanan, Mohamed, Wolff, Robert A, Yao, James C, Mahvash, Armeen

Get full text